• Je něco špatně v tomto záznamu ?

Hypoparathyroidism: an uncommon adverse effect of treatment with durvalumab

A. Kreze, M. Homer, T. Barešová, K. Klemperová

. 2022 ; 2 (1) : K21-K24. [pub] 20220922

Status neindexováno Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu kazuistiky

Perzistentní odkaz   https://www.medvik.cz/link/bmc23015927

SUMMARY: Immune checkpoint inhibitors (ICIs) are monoclonal antibodies approved for the treatment of numerous cancer types. Toxicities induced by ICIs may affect any organ system and manifest as endocrinopathy. The main side effects related to treatment are immune-related adverse events (irAEs), especially thyroid dysfunction and hypophysitis. Rare endocrine irAEs are diabetes insipidus, hypoparathyroidism, thyrotoxic crisis and hypogonadism. We report a case of hypoparathyroidism induced by ICI treatment with durvalumab, which has not previously been described. LEARNING POINTS: Treatment with immune checkpoint inhibitors (ICIs) is associated with many endocrine side effects.It is recommended that patients treated with ICIs are observed by an endocrinologist.If side effects are treated accordingly, ICI therapy can continue.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23015927
003      
CZ-PrNML
005      
20231101114540.0
007      
ta
008      
231010s2022 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1530/EO-22-0047 $2 doi
035    __
$a (PubMed)37435467
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Kreze, Alexander $u Endocrine Clinic of Internal Medicine Department, The Bulovka University Hospital, Praha, Czech Republic $u Department of Internal Medicine, The Bulovka University Hospital, Praha, Czech Republic $1 https://orcid.org/0000000236945626 $7 xx0070905
245    10
$a Hypoparathyroidism: an uncommon adverse effect of treatment with durvalumab / $c A. Kreze, M. Homer, T. Barešová, K. Klemperová
520    9_
$a SUMMARY: Immune checkpoint inhibitors (ICIs) are monoclonal antibodies approved for the treatment of numerous cancer types. Toxicities induced by ICIs may affect any organ system and manifest as endocrinopathy. The main side effects related to treatment are immune-related adverse events (irAEs), especially thyroid dysfunction and hypophysitis. Rare endocrine irAEs are diabetes insipidus, hypoparathyroidism, thyrotoxic crisis and hypogonadism. We report a case of hypoparathyroidism induced by ICI treatment with durvalumab, which has not previously been described. LEARNING POINTS: Treatment with immune checkpoint inhibitors (ICIs) is associated with many endocrine side effects.It is recommended that patients treated with ICIs are observed by an endocrinologist.If side effects are treated accordingly, ICI therapy can continue.
590    __
$a NEINDEXOVÁNO
655    _2
$a kazuistiky $7 D002363
700    1_
$a Homer, Matěj $u Department of Internal Medicine, The Bulovka University Hospital, Praha, Czech Republic $7 xx0308569
700    1_
$a Barešová, Tereza $u Department of Internal Medicine, The Bulovka University Hospital, Praha, Czech Republic $7 xx0308568
700    1_
$a Klemperová, Kristina $u Department of Biochemistry, The Bulovka University Hospital, Praha, Czech Republic $7 xx0239755
773    0_
$w MED00213972 $t Endocrine oncology (Bristol, England) $x 2634-4793 $g Roč. 2, č. 1 (2022), s. K21-K24
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37435467 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20231010 $b ABA008
991    __
$a 20231101114536 $b ABA008
999    __
$a ok $b bmc $g 1997316 $s 1202289
BAS    __
$a 3
BAS    __
$a PreBMC-PubMed-not-MEDLINE
BMC    __
$a 2022 $b 2 $c 1 $d K21-K24 $e 20220922 $i 2634-4793 $m Endocrine oncology $n Endocr Oncol $x MED00213972
LZP    __
$b NLK198 $a Pubmed-20231010

Najít záznam

Citační ukazatele

Možnosti archivace